ODF2L and cancer: Combination treatment of ODF2L-targeted therapy via an siRNA-loaded LNP would be expected to benefit patients experiencing severe side effects such as histopathological toxicity after receiving a relatively high dose of a WEE1 inhibitor alone, or patients who have received WEE1 inhibitor–based therapy but whose cancer recurred, in part because of the induction of ODF2L during the treatment.